Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAd-p53 + Chemoradiotherapy in Head and Neck Cancer
NCT02429037Phase 2Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- May 2015
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human p53 adenovirus injection in head and neck cancer (HNC), sponsored by Shenzhen SiBiono GeneTech. Status: unknown.
02
Drugs
recombinant human p53 adenovirus injection
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02429037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429037.